** U.S.-listed shares of Scinai Immunotherapeutics 2F5y.F, SCNI.O rise 104% to $5.15
** Stock set for its best day on record, if gains hold
** Co says it received Italian government's clearance to potentially acquire Italian biotech firm Pincell, which is developing novel antibody to treat severe skin conditions
** Approval removes major regulatory hurdle for acquisition but does not finalize deal, SCNI says
** Scinai plans to acquire 100% of Pincell's share capital and voting rights
** Acquisition, initially agreed in March, still requires meeting additional conditions before completion, co says
** Pincell's lead drug, antibody PC111, is being developed to treat rare and severe skin disorders
** Including session's moves, SCNI up 54.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。